Hep C Treatment

Hepatitis C: Treatment and Management


Pooled safety data: ledipasvir/sofosbuvir: HCV-1

Posted on May 17, 2015

Pooled analysis of safety data from the three multicenter, randomized, open-label ION Phase 3 clinical trials shows that the addition of ribavirin to ledipasvir/sofosbuvir HCV-1 treatment regimens increased toxicity without providing additional efficacy. Eliminating ribavirin from HCV therapy will likely increase patient adherence to treatment due to an improved quality of life resulting from fewer adverse events, less laboratory monitoring, the ...

Read More


Largest DAA study to date in HCV genotype 4

Largest study to date shows that the two direct-acting antiviral drug-only regimen (ombitasvir plus paritaprevir) is effective and well tolerated in both treatment-naive and treatment-experienced patients with HCV genotype 4 infection without cirrhosis. Note that patients also received low-dose ritonavir to increase paritaprevir peak and trough concentrations and overall drug exposure. HCV genotype 4 is a heterogeneous genotype with multiple ...

Read More


Newly Updated EASL 2015 HCV Guidelines

Posted on May 5, 2015

EASL 2015 HCV Guideline Recommendations: Summary Document and Full Report are Now Available for Download in Our American Journal of Medicine Hepatitis C Resource Center The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress, which took place last month in Vienna, Austria. Liz Highleyman, in collaboration with hivandhepatitis.com, has written an ...

Read More


DAA HCV Regimen effective in pts with cirrhosis

Interferon free, direct acting antiviral HCV regimen ledipasvir-sofosbuvir with and without ribavirin is effective and well tolerated in adult patients with HCV genotype 1 and cirrhosis who have failed previous HCV therapy Chronically infected patients with cirrhosis, especially those who have failed previous hepatitis C therapy, achieve consistently lower rates of SVR than those without cirrhosis, in both clinical trials and real-world ...

Read More


Response rates to HCV treatment in the real world

Posted on May 1, 2015

Approximately 30 to 40 patients with HCV infection are treated annually with the best evidence-based treatment at the Barwon Health Liver Clinic, a 406-bed tertiary care teaching hospital located in Geelong, Victoria, Australia. Being a single hospital, Barwon Health Liver Clinic has more limited nursing and medical resources compared with those provided in large multinational clinical trials. N. Deborah Friedman and colleagues conducted a ...

Read More


EASL 2015 HCV Vaccine Lecture: Dr T. Baumert

Posted on April 29, 2015

  Please click here to view this important EASL 2015 HCV presentation by Thomas F. Baumert, MD. Thomas F. Baumert, MD is Professor of Medicine, head of Inserm Research Unit U1110, Institute of Viral and Liver Diseases, head of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Physician at the Center for Digestive Disease and Hepatology at the Strasbourg University Hospitals. He received his MD from the ...

Read More


Treating hepatitis C in difficult-to-treat patients

Interferon-free treatment regimens are highly effective, well-tolerated, and enable clinicians to treat patients with hepatitis C who cannot be treated with interferon-based regimens. In a review article recently published in the journal Nature Reviews Gastroenterology & Hepatology, Peter Ferenci, MD, describes and assesses the application of interferon-free treatment in previously untreatable patients (Ferenci P. Nat Rev Gastroenterol ...

Read More


Effective HCV therapy in HIV coinfected patients

PHOTON-2 study results confirm the findings of PHOTON-1: sofosbuvir and ribavirin provide high rates of sustained virological response in patients with HCV genotypes 1–3 who are co-infected with HIV. PHOTON-2 also provides the first clinical evidence that an interferon-free regimen can be highly effective for treatment of HCV genotype 4 in patients co-infected with HIV. HIV exacerbates the morbidity of patients with HCV, even in those ...

Read More


Successful HCV virus eradication is durable

Posted on April 15, 2015

Study reconfirms that successful anti-HCV therapy translates into increased patient survival at least in chronically infected patients with advanced stages of fibrosis. Achieving SVR did not entirely prevent hepatic decompensation or HCC, which adds further credence to continued long-term surveillance for HCC in SVR patients. Long-term complications of chronic hepatitis C infection including liver cirrhosis, portal hypertension and hepatoce...

Read More


Treatment-induced SVR is a long-term HCV cure

Posted on April 15, 2015

Study indicates that a treatment-induced SVR corresponds to a cure for Hepatitis C, and that the clinical significance of any residual trace amounts of HCV RNA seems limited A sustained viral response (SVR), defined as undetectable HCV RNA in serum 24 weeks after the end of treatment, is regarded as a cure from HCV infection. However, it has been hypothesized that residual foci of HCV infected cells with low HCV replication may still be ...

Read More